Canada markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7350-0.0212 (-2.80%)
At close: 04:00PM EST
Currency in USD

Valuation Measures4

Market Cap (intraday) 94.87M
Enterprise Value 836.71k
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.97
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.03

Trading Information

Stock Price History

Beta (5Y Monthly) 1.21
52-Week Change 313.43%
S&P500 52-Week Change 316.10%
52 Week High 31.3900
52 Week Low 30.5000
50-Day Moving Average 30.7032
200-Day Moving Average 30.8178

Share Statistics

Avg Vol (3 month) 3354.01k
Avg Vol (10 day) 3309.65k
Shares Outstanding 5125.3M
Implied Shares Outstanding 6125.3M
Float 8117.5M
% Held by Insiders 10.08%
% Held by Institutions 119.56%
Shares Short (Nov 14, 2023) 46.37M
Short Ratio (Nov 14, 2023) 421.32
Short % of Float (Nov 14, 2023) 45.09%
Short % of Shares Outstanding (Nov 14, 2023) 45.09%
Shares Short (prior month Oct 12, 2023) 47.05M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Apr 19, 2018
Ex-Dividend Date 4N/A
Last Split Factor 21:12
Last Split Date 3Apr 19, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Sept 29, 2023


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-16.69%
Return on Equity (ttm)-26.86%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -30.48M
Net Income Avi to Common (ttm)-29.83M
Diluted EPS (ttm)-0.2400
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)94.03M
Total Cash Per Share (mrq)0.75
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)28.35
Book Value Per Share (mrq)0.78

Cash Flow Statement

Operating Cash Flow (ttm)-19.89M
Levered Free Cash Flow (ttm)-10.44M